Inflammatory markers and longitudinal lung function decline in the elderly.

Longitudinal studies examining associations of the inflammatory markers fibrinogen and C-reactive protein (CRP) with lung function decline are sparse. The authors examined whether elevated fibrinogen and CRP levels were associated with greater longitudinal lung function decline in the elderly. The Cardiovascular Health Study measured fibrinogen and CRP in 5,790 Whites and African Americans from four US communities aged 65 years or older in 1989-1990 or 1992-1993. Spirometry was performed in 1989-1990 and 4, 7, and 16 years later. Fibrinogen and CRP were inversely associated with lung function at baseline after adjustment for multiple potential confounders. In mixed models, the rate of decline in forced expiratory volume in 1 second (FEV(1))/forced vital capacity (FVC) ratio with increasing age was faster among those with higher baseline fibrinogen (-0.032%/year per standard deviation higher fibrinogen (95% confidence interval: -0.057, -0.0074)) but not among those with higher CRP (-0.0037%/year per standard deviation higher CRP (95% confidence interval: -0.013, 0.0056)). Longitudinal analyses for FEV(1) and FVC yielded results in the direction opposite of that hypothesized, possibly because of the high mortality rate and strong inverse association of FEV(1) and FVC but not FEV(1)/FVC with mortality. An alternative approach to missing data yielded similar results. In conclusion, higher levels of fibrinogen, but not CRP, independently predicted greater FEV(1)/FVC decline in the elderly.

[1]  Standardization of spirometry--1987 update. Statement of the American Thoracic Society. , 1987, The American review of respiratory disease.

[2]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[3]  Angshu Bhowmik,et al.  Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. , 2009, Chest.

[4]  A. Brody,et al.  Analysis of airspace and interstitial mononuclear cell populations in human diffuse interstitial lung disease. , 2015, The American review of respiratory disease.

[5]  B. Hedblad,et al.  Lung Function and Cardiovascular Risk: Relationship With Inflammation-Sensitive Plasma Proteins , 2002, Circulation.

[6]  Graham Devereux,et al.  Definition, epidemiology, and risk factors , 2006, BMJ : British Medical Journal.

[7]  D. Sin,et al.  The interactions between cigarette smoking and reduced lung function on systemic inflammation. , 2005, Chest.

[8]  C. Lewis,et al.  Plasma fibrinogen and lung function: the CARDIA Study. , 2006, International journal of epidemiology.

[9]  M. Zureik,et al.  Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. , 2006, Respiratory medicine.

[10]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[11]  B. Nordestgaard,et al.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[12]  G. Valdivia,et al.  The long-term stability of portable spirometers used in a multinational study of the prevalence of chronic obstructive pulmonary disease. , 2006, Respiratory care.

[13]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[14]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[15]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[16]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[17]  Buist As Standardization of spirometry. , 1987 .

[18]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[19]  S. Hurd,et al.  The impact of COPD on lung health worldwide: epidemiology and incidence. , 2000, Chest.

[20]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[21]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[22]  T. McKeever,et al.  Systemic inflammation and decline in lung function in a general population: a prospective study , 2007, Thorax.

[23]  D. Hoyert,et al.  Deaths: preliminary data for 2003. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[24]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[25]  J. Soriano,et al.  C-reactive protein in patients with COPD, control smokers and non-smokers: Thorax 2006;61:23–8 , 2006 .

[26]  P. Enright,et al.  Predictors of loss of lung function in the elderly: the Cardiovascular Health Study. , 2001, American journal of respiratory and critical care medicine.

[27]  M. Zureik,et al.  Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study , 2004, Thorax.

[28]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[29]  Joseph L Schafer,et al.  Analysis of Incomplete Multivariate Data , 1997 .

[30]  E. Arias,et al.  Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.